These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 436896)

  • 21. Immunological studies in melanoma patients treated with BCG.
    De Vries JE; Rümke P
    Br J Cancer Suppl; 1973 Aug; 1():97-102. PubMed ID: 4804294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE; Levin AS; Wybran J
    Cell Immunol; 1976 Jan; 21(1):1-19. PubMed ID: 764975
    [No Abstract]   [Full Text] [Related]  

  • 24. Malignant melanoma.
    Lichtenfeld JL
    Med Clin North Am; 1977 Sep; 61(5):1013-25. PubMed ID: 330971
    [No Abstract]   [Full Text] [Related]  

  • 25. Heterogeneity of melanoma-associated antigens detected by sera from patients receiving adjuvant allogeneic tumor vaccine immunotherapy.
    Dent PB; McCulloch PB; Liao SK; Stone BR; Singal DP
    Clin Immunol Immunopathol; 1982 May; 23(2):379-91. PubMed ID: 6980756
    [No Abstract]   [Full Text] [Related]  

  • 26. Chemotherapy of melanoma.
    Luce JK
    Semin Oncol; 1975 Jun; 2(2):179-85. PubMed ID: 1234375
    [No Abstract]   [Full Text] [Related]  

  • 27. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoimmunotherapy of human solid tumors.
    Gutterman JU; Mavligit GM; Hersh EM
    Med Clin North Am; 1976 May; 60(3):441-62. PubMed ID: 1063907
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical results with immunochemotherapy in 40 cases of advanced tumour.
    Narcisi M
    Panminerva Med; 1975; 17(5-6):208-10. PubMed ID: 1161322
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patient: association with BCG immunotherapy and clinical deterioration.
    Levy NL; Mahaley MS; Day ED
    Int J Cancer; 1972 Sep; 10(2):244-8. PubMed ID: 4661092
    [No Abstract]   [Full Text] [Related]  

  • 31. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoimmunotherapy of small cell bronchogenic carcinoma.
    Holoye PY; Samuels ML; Smith T; Sinkovics JG
    Cancer; 1978 Jul; 42(1):34-40. PubMed ID: 208755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current concepts in the management of malignant melanoma.
    Lichtenfeld JL
    Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
    [No Abstract]   [Full Text] [Related]  

  • 34. Malignant melanoma.
    Moore GE; Gerner RE
    Surg Gynecol Obstet; 1971 Mar; 132(3):427-36. PubMed ID: 5546295
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of recurrent melanoma of the extremity.
    Shingleton WW; Seigler HF; Stocks LH; Downs RW
    Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG
    Surg Clin North Am; 1981 Dec; 61(6):1267-77. PubMed ID: 7031934
    [No Abstract]   [Full Text] [Related]  

  • 38. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemoimmunotherapy of acute leukemia in children.
    Bergolz VM; Kisljak NS; Eremeev VS; Rumjanzev AG; Akimova GV; Molochkina AM; Osipov SG
    Neoplasma; 1978; 25(3):359-63. PubMed ID: 277786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
    Currie GA; McElwain TJ
    Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.